BiotechTube
RS Synthesis

RS Synthesis

San Diego, United States· Est.
rssynthesis.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10M

Overview

RS Synthesis is a privately-held contract development and manufacturing organization (CDMO) focused on peptide synthesis. Founded in 2015 and headquartered in San Diego, it serves the pharmaceutical, biotechnology, and cosmetic industries with services spanning from milligram-scale research peptides to kilogram-scale Good Manufacturing Practice (GMP) active pharmaceutical ingredients (APIs). Its business model is service-oriented, generating revenue by providing custom synthesis, library production, and antibody services to client organizations globally.

Small MoleculesDrug Delivery

Technology Platform

Fmoc-based solid-phase peptide synthesis (SPPS) with capabilities for high-throughput synthesis, scale-up to kilogram quantities, and GMP manufacturing. Supported by analytical QC (HPLC, Mass Spec).

Funding History

2
Total raised:$10M
Series A$8M
Seed$2M

Opportunities

The growing global market for peptide therapeutics and cosmetic peptides drives demand for reliable CDMO services.
Expansion through international distributors and scaling high-margin GMP/API manufacturing present significant growth opportunities.

Risk Factors

Key risks include intense competition in the peptide CDMO space, reliance on client R&D budgets which are cyclical, and significant regulatory compliance burdens for GMP manufacturing.
Supply chain vulnerabilities for specialty raw materials also pose a threat.

Competitive Landscape

RS Synthesis competes in a fragmented but competitive global peptide CDMO market against large players like Bachem and PolyPeptide Group, as well as numerous mid-sized and low-cost providers, particularly from Asia. Differentiation is based on price, speed, quality, and customer service.

More companies in Biologics / Biosimilars →More companies in United States →